Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant

Larisa Broglie*, Irene Helenowski, Lawrence J. Jennings, Kristian T Schafernak, Reggie Duerst, Jennifer Schneiderman, William T Tse, Morris Kletzel, Sonali Chaudhury

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Patients with acute myeloid leukemia (AML) who relapse after hematopoietic stem cell transplantation (HCT) have dismal outcomes. Our ability to predict those at risk for relapse is limited. We examined chimerism trends post-HCT in 63 children who underwent HCT for AML or myelodysplastic syndrome (MDS). Mixed T-cell chimerism at engraftment and absence of chronic graft versus host disease (cGVHD) were associated with relapse (P = 0.04 and P = 0.02, respectively). Mixed T-cell chimerism at engraftment was predictive in patients without cGVHD (P = 0.03). Patients with engraftment mixed T-cell chimerism may warrant closer disease monitoring and consideration for early intervention.

Original languageEnglish (US)
Article numbere26493
JournalPediatric Blood and Cancer
Volume64
Issue number9
DOIs
StatePublished - Sep 1 2017

Keywords

  • AML
  • HCT
  • chimerism
  • pediatrics
  • relapse

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant'. Together they form a unique fingerprint.

  • Cite this